Felix Bokstein
- 46年の経験
- 所在地: イスラエル, テルアビブ
Head of Neurooncology Clinic of Ichilov
イスラエルのトップグリオーマ医師と価格を比較。こちらで最適なマッチングを見つけてください
ご要望と予算に基づいて最適な医師を厳選いたします
医学的監修者 Fahad Mawlood
医学編集者・データサイエンティストトップ医師
4
イスラエル
レビュー
14000+
実際の患者より
個別化された治療計画を無料で取得し、最良のオプションを選択してください。コミットメント不要 · サービス料金なし
最初に表示:
Head of Neurooncology Clinic of Ichilov
この医師は、脳および脊髄腫瘍の治療に焦点を当てた非常に経験豊富な神経腫瘍学者です。彼女は1996年から1998年までMemorial Sloan-Kettering Cancer Centerで神経腫瘍学の訓練を修了しました。1998年以降、彼女はシニア神経腫瘍学者として勤務し、広範な臨床専門知識を示しています。彼女は1998年から2005年までユタ大学のHuntsman Cancer Instituteで神経腫瘍学サービスのディレクターを務め、神経腫瘍学的ケアの進展を主導しました。<\/p>
シュロミー・コンスタンティーニ教授は、イスラエルで最も優れた脳神経外科医の一人です。彼は、成人と子供の神経外科的ケアの専門家です。コンスタンティーニ教授はイスラエルのハダサ医科大学を卒業し、以下の訓練を受けました:
医師の専門は、一般および小児脳神経外科です。彼は、子供の脳および脊髄腫瘍の治療を提供し、骨構造に関する先天性および新生児の障害に取り組んでいます。シュロミー・コンスタンティーニ教授は、微細手術、再建的介入、脳血管瘤の外科的修正の専門家です。
コンスタンティーニ博士は、神経内視鏡、脳研究、および小児脳偶発腫瘍に関する研究活動を行っています。
この医師は、著名な神経外科医であり、現在、European Association of Neurosurgical Societies (EANS) の会長を務めています。テルアビブ大学のサックラー医学部を卒業し、チャイム・シェバ医療センターでのローテーションインターンシップを修了し、アメリカのAmerican Association of Neurosurgeryと協力しました。動脈瘤、脳血管病変、脳腫瘍、最小侵襲の脳および脊椎手術などの疾患を専門とし、脳マッピングや深部脳刺激 (DBS) にも精通しています。神経学への貢献により、ボレンスタイン賞とゴールドヒルシュ財団賞を受賞しています。
海外のクリニックを選ぶことはストレスフルです。800,000名以上の患者をサポートしたBookimedは、お客様の懸念を理解しています。信頼できる医師、最高の価格品質オプション、複雑なケースの解決策を見つける方法を知っています。すべての段階でお客様をご案内いたします。
ヤン・マツィイフスキー
医療コーディネーターチーム責任者
4300+件以上の患者の旅をガイド
Bookimedで3年
Israelの142名の患者が今月当社を通じて医師を見つけました
2分のクイズ
目標、予算、スケジュールをお聞かせください
人間のマッチング + AI
アルゴリズムがマッチングを見つけ、コーディネーターが適合性を確認します
オプション準備完了
価格、パッケージ、日程を比較。コーディネーターとチャット
選択肢に迷っていますか?
治療をガイド
医療訓練を受けた専属コーディネーター






| 順位 | 医師 | 経験 | 適合する方 | 特色 | クリニックと所在地 | 診察 |
|---|
Top specialists for glioma and glioblastoma in Israel include Prof. Zvi Ram, Prof. Zvi Cohen, and Dr. Felix Bokstein. These experts lead neuro-oncology units at JCI-accredited centers in Tel Aviv and Ramat Gan, specializing in complex tumor removal and gene-based cancer therapies for adult and pediatric patients.
Bookimed Expert Insight: Patients seeking treatment for glioblastoma in Israel benefit from a multidisciplinary infrastructure. Specialists like Prof. Zvi Cohen lead dedicated brain tumor tissue banks. This resource allows doctors to research drug therapies specifically tailored to the unique molecular profile of a patient's tumor.
Patient Consensus: Patients emphasize that Israeli specialists often provide more intensive surgical options for glioblastoma than other centers. Many recommend getting MRI scans reviewed early by these experts, as specialized centers sometimes find surgical possibilities that general oncology teams might overlook.
Glioma surgeons in Israel are experts who hold board certifications and leadership roles in neuro-oncology. Specialists like Dr. Zvi Cohen and Dr. Felix Bokstein often have over 30 years of clinical experience. They typically complete fellowships at top institutions like MD Anderson or Memorial Sloan-Kettering Cancer Center.
Bookimed Expert Insight: Israeli specialists often hold dual qualifications in neurosurgery and neuro-oncology. For example, Dr. Felix Bokstein and Dr. Dvora Blumental lead specialized clinics at Sourasky Medical Center. They focus exclusively on brain tumors, which is more specialized than general neurosurgery seen in many regional hospitals.
Patient Consensus: Patients mention that Israeli specialists offer a sense of cautious optimism for complex brain tumor cases. They noticed that surgeons focus heavily on preserving brain function while removing as much tumor as possible. Those treated often felt reassured by the deep international training their doctors received in the United States.
Israeli neurosurgeons use advanced tools like intraoperative MRI, neuronavigation, and brain mapping to protect vital functions. Experts like Dr. Zvi Cohen at Sheba Medical Center integrate real-time imaging with stereotactic systems to maximize glioma removal while preserving the patient's speech and motor skills.
Bookimed Expert Insight: Israeli specialists often combine surgical roles with neuro-oncology leadership to provide more integrated care. For example, Dr. Zvi Cohen leads both the Neurosurgery Department and the Neuro-Oncology Unit at Sheba. This dual expertise allows surgeons to decide intraoperatively whether to pursue aggressive resection or transition to targeted therapies based on the tumor's biology.
Patient Consensus: Patients are often surprised to remain awake during surgery, but found that performing tasks helped the surgeon protect their ability to speak. They noted that the highly targeted technology felt more like a precise technical procedure than traditional surgery.
Israeli glioma specialists are deeply integrated into international research. They lead the European Association of Neurosurgical Societies and hold memberships in prominent American and European neuro-oncology associations. Many participate in global clinical trials for brain cancer treatments and collaborate with top hospitals like MD Anderson Cancer Center.
Bookimed Expert Insight: Israeli specialists often bridge the gap between lab research and clinical practice. For instance, Dr. Zvi Cohen established a brain tumor tissue bank at Sheba for drug research. This allows doctors to test newer drug therapies for malignant gliomas directly on tumor samples, speeding up treatment innovations.
Patient Consensus: Patients feel more hopeful when their doctor is connected to a wider network of researchers. They value specialists who actively locate international trials even if the treatments are not yet locally available.
Glioma specialists in Israel report surgical success rates of 85–90% for tumor removals at JCI-accredited centers. These outcomes are driven by neurosurgeons using brain mapping and intraoperative MRI to maximize resection. For low-grade gliomas, many Israeli clinics report 5-year survival rates reaching up to 90%.
Bookimed Expert Insight: Israeli specialists often combine surgical mastery with intensive research in gene-based and immune therapies. For example, Dr. Zvi Ram researches gene-based treatments, and Dr. Dvora Blumental trained at Memorial Sloan-Kettering. This dual focus allows doctors to offer innovative options when standard protocols for aggressive gliomas show limited results.
Patient Consensus: Patients find hope in long-term survival stories, including those who remain tumor-free for 10+ years. Many choose Israel to access clinical trials or immunotherapy when conventional options feel insufficient. Families often notice the stability of outcomes for low-grade cases, where some stay disease-free for years.